Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-10-05

AUTHORS

Yoshikazu Utsu, Koji Takaishi, Shunichirou Inagaki, Hironori Arai, Hiromi Yuasa, Shinichi Masuda, Yasuhiro Matsuura, Nobuyuki Aotsuka, Hisashi Wakita

ABSTRACT

Dose intensity (DI) of chemotherapy affects prognosis of diffuse large B cell lymphoma (DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for hematological malignancies, whereas DLT of vincristine (VCR) is mainly neurological toxicity. Although VCR is a key drug and its combination with other cytotoxic agents needs consideration, studies focused on relative DI (RDI) of VCR have not been done before. We retrospectively analyzed 86 cases of DLBCL that received six or more cycles of cyclophosphamide (CPM), doxorubicin (DXR), VCR, prednisolone, and rituximab [R-CHOP] and calculated RDI of each cytotoxic agent to analyze its influence on treatment outcome. The median RDI of CPM, doxorubicin, and VCR was 80.0, 81.7, and 78.4 %, respectively (p = 0.002). The average RDI (ARDI) of these three agents was 80.0 %. The overall survival was significantly worse in the low ARDI (<85 %) than in the high ARDI (>85 %) group (2-year survival rate 67.2 vs 93.4 %, p = 0.011). The survival rate with low RDI VCR (<85 %) was lower than that with high RDI VCR (>85 %), even when the remaining two agents had high ARDI (2-year survival rate 74.3 vs 95.8 %, p = 0.047). In conclusion, VCR dose tended to be reduced compared with CPM and DXR in R-CHOP. Lower ARDI of cytotoxic agents and lower RDI of VCR could lead to poor prognosis in the treatment of DLBCL with R-CHOP. We thought these observations should be confirmed in a prospective study. More... »

PAGES

41-47

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9

DOI

http://dx.doi.org/10.1007/s00277-015-2514-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013177223

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26435364


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Murine-Derived", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Large B-Cell, Diffuse", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Utsu", 
        "givenName": "Yoshikazu", 
        "id": "sg:person.01007725661.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007725661.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takaishi", 
        "givenName": "Koji", 
        "id": "sg:person.0776770323.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776770323.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inagaki", 
        "givenName": "Shunichirou", 
        "id": "sg:person.01256762775.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256762775.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arai", 
        "givenName": "Hironori", 
        "id": "sg:person.01325076175.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325076175.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuasa", 
        "givenName": "Hiromi", 
        "id": "sg:person.0601472075.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601472075.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masuda", 
        "givenName": "Shinichi", 
        "id": "sg:person.01124154261.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124154261.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsuura", 
        "givenName": "Yasuhiro", 
        "id": "sg:person.01216742571.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216742571.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aotsuka", 
        "givenName": "Nobuyuki", 
        "id": "sg:person.0577376767.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577376767.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459661.9", 
          "name": [
            "Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wakita", 
        "givenName": "Hisashi", 
        "id": "sg:person.0656507753.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656507753.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12885-015-1287-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021003853", 
          "https://doi.org/10.1186/s12885-015-1287-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-007-0399-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037563009", 
          "https://doi.org/10.1007/s00277-007-0399-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2012.244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028358194", 
          "https://doi.org/10.1038/bmt.2012.244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-9966-28-116", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027098559", 
          "https://doi.org/10.1186/1756-9966-28-116"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-010-0956-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002676992", 
          "https://doi.org/10.1007/s00277-010-0956-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-10-05", 
    "datePublishedReg": "2015-10-05", 
    "description": "Dose intensity (DI) of chemotherapy affects prognosis of diffuse large B cell lymphoma (DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for hematological malignancies, whereas DLT of vincristine (VCR) is mainly neurological toxicity. Although VCR is a key drug and its combination with other cytotoxic agents needs consideration, studies focused on relative DI (RDI) of VCR have not been done before. We retrospectively analyzed 86 cases of DLBCL that received six or more cycles of cyclophosphamide (CPM), doxorubicin (DXR), VCR, prednisolone, and rituximab [R-CHOP] and calculated RDI of each cytotoxic agent to analyze its influence on treatment outcome. The median RDI of CPM, doxorubicin, and VCR was 80.0, 81.7, and 78.4\u00a0%, respectively (p\u2009=\u20090.002). The average RDI (ARDI) of these three agents was 80.0\u00a0%. The overall survival was significantly worse in the low ARDI (<85\u00a0%) than in the high ARDI (>85\u00a0%) group (2-year survival rate 67.2 vs 93.4\u00a0%, p\u2009=\u20090.011). The survival rate with low RDI VCR (<85\u00a0%) was lower than that with high RDI VCR (>85\u00a0%), even when the remaining two agents had high ARDI (2-year survival rate 74.3 vs 95.8\u00a0%, p\u2009=\u20090.047). In conclusion, VCR dose tended to be reduced compared with CPM and DXR in R-CHOP. Lower ARDI of cytotoxic agents and lower RDI of VCR could lead to poor prognosis in the treatment of DLBCL with R-CHOP. We thought these observations should be confirmed in a prospective study.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-015-2514-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "95"
      }
    ], 
    "keywords": [
      "diffuse large B-cell lymphoma", 
      "dose-limiting toxicity", 
      "large B-cell lymphoma", 
      "average RDI", 
      "B-cell lymphoma", 
      "R-CHOP", 
      "dose intensity", 
      "cytotoxic agents", 
      "relative di", 
      "cell lymphoma", 
      "major dose-limiting toxicity", 
      "treatment of DLBCL", 
      "relative dose intensity", 
      "most cytotoxic agents", 
      "cases of DLBCL", 
      "VCR dose", 
      "overall survival", 
      "neurological toxicity", 
      "prospective study", 
      "poor prognosis", 
      "key drug", 
      "treatment outcomes", 
      "hematological malignancies", 
      "dose reduction", 
      "cyclophosphamide", 
      "vincristine", 
      "survival rate", 
      "doxorubicin", 
      "prognosis", 
      "lymphoma", 
      "more cycles", 
      "outcomes", 
      "agents", 
      "toxicity", 
      "myelotoxicity", 
      "prednisolone", 
      "chemotherapy", 
      "malignancy", 
      "dose", 
      "drugs", 
      "survival", 
      "treatment", 
      "study", 
      "conclusion", 
      "group", 
      "cases", 
      "rate", 
      "reduction", 
      "combination", 
      "influence", 
      "cycle", 
      "intensity", 
      "observations", 
      "consideration"
    ], 
    "name": "Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma", 
    "pagination": "41-47", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013177223"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-015-2514-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26435364"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-015-2514-9", 
      "https://app.dimensions.ai/details/publication/pub.1013177223"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_660.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-015-2514-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2514-9'


 

This table displays all metadata directly associated to this object as RDF triples.

267 TRIPLES      21 PREDICATES      103 URIs      90 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-015-2514-9 schema:about N0bd48295e67f434d964abdc8c34f6c9c
2 N0db21f88ebc444ad9b252be2d9df81fe
3 N11cd9cc1ffd74c5f953a47639970af9d
4 N13dc4b4d5c054141b8cb893c28f8c554
5 N1fa0260329a6497fbf1f34a593ab3eed
6 N31b142c3fac44dc2a1c784793b906863
7 N4ed71fb1e8884a6c9ea7f53c37eb2360
8 N63e867d4cfe94d36b59dfbb8186bcdc0
9 N65f5f94ab2b24d138bb22a8dfcd6a5e3
10 N802e6cffd88140889f9c7204860f531d
11 N8c1354d9860e4ac29076a028f9ad5d87
12 N9008329ef4af4f24a5b1482404b70f18
13 N909b52e9ecec4fc58402c9e1ae9be8f4
14 N9dbb56e8fa924c6096243d834f397b36
15 Nbe82df0311104ea3afffb921c7cc4b48
16 Nc402c8ae638a48a4955fa7bfdda897c8
17 Nd069e81474e749fabdf09bac5ed5d557
18 Ne87110c9192f4837b68615be96b0bb6d
19 Necec8cf130f04a8b88a2143933cd5253
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N6d0359c80c9643e6b2ae2bc78ffc5536
23 schema:citation sg:pub.10.1007/s00277-007-0399-y
24 sg:pub.10.1007/s00277-010-0956-7
25 sg:pub.10.1038/bmt.2012.244
26 sg:pub.10.1186/1756-9966-28-116
27 sg:pub.10.1186/s12885-015-1287-9
28 schema:datePublished 2015-10-05
29 schema:datePublishedReg 2015-10-05
30 schema:description Dose intensity (DI) of chemotherapy affects prognosis of diffuse large B cell lymphoma (DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for hematological malignancies, whereas DLT of vincristine (VCR) is mainly neurological toxicity. Although VCR is a key drug and its combination with other cytotoxic agents needs consideration, studies focused on relative DI (RDI) of VCR have not been done before. We retrospectively analyzed 86 cases of DLBCL that received six or more cycles of cyclophosphamide (CPM), doxorubicin (DXR), VCR, prednisolone, and rituximab [R-CHOP] and calculated RDI of each cytotoxic agent to analyze its influence on treatment outcome. The median RDI of CPM, doxorubicin, and VCR was 80.0, 81.7, and 78.4 %, respectively (p = 0.002). The average RDI (ARDI) of these three agents was 80.0 %. The overall survival was significantly worse in the low ARDI (<85 %) than in the high ARDI (>85 %) group (2-year survival rate 67.2 vs 93.4 %, p = 0.011). The survival rate with low RDI VCR (<85 %) was lower than that with high RDI VCR (>85 %), even when the remaining two agents had high ARDI (2-year survival rate 74.3 vs 95.8 %, p = 0.047). In conclusion, VCR dose tended to be reduced compared with CPM and DXR in R-CHOP. Lower ARDI of cytotoxic agents and lower RDI of VCR could lead to poor prognosis in the treatment of DLBCL with R-CHOP. We thought these observations should be confirmed in a prospective study.
31 schema:genre article
32 schema:isAccessibleForFree false
33 schema:isPartOf N582b67e998054a1fb6250a61ddc08625
34 Nc0711977d0264f68b48890d5b0f7c761
35 sg:journal.1358129
36 schema:keywords B-cell lymphoma
37 R-CHOP
38 VCR dose
39 agents
40 average RDI
41 cases
42 cases of DLBCL
43 cell lymphoma
44 chemotherapy
45 combination
46 conclusion
47 consideration
48 cycle
49 cyclophosphamide
50 cytotoxic agents
51 diffuse large B-cell lymphoma
52 dose
53 dose intensity
54 dose reduction
55 dose-limiting toxicity
56 doxorubicin
57 drugs
58 group
59 hematological malignancies
60 influence
61 intensity
62 key drug
63 large B-cell lymphoma
64 lymphoma
65 major dose-limiting toxicity
66 malignancy
67 more cycles
68 most cytotoxic agents
69 myelotoxicity
70 neurological toxicity
71 observations
72 outcomes
73 overall survival
74 poor prognosis
75 prednisolone
76 prognosis
77 prospective study
78 rate
79 reduction
80 relative di
81 relative dose intensity
82 study
83 survival
84 survival rate
85 toxicity
86 treatment
87 treatment of DLBCL
88 treatment outcomes
89 vincristine
90 schema:name Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma
91 schema:pagination 41-47
92 schema:productId N94db93691a024e5bb95c1fbb555bbe50
93 Na6f7ac0da1b64bcf88ae2fefaed68ba6
94 Nea157dd65df449a2bae90ff63f107f3a
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013177223
96 https://doi.org/10.1007/s00277-015-2514-9
97 schema:sdDatePublished 2022-10-01T06:40
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N6c96d9c836af44ce98742fc75618b35d
100 schema:url https://doi.org/10.1007/s00277-015-2514-9
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N0bd48295e67f434d964abdc8c34f6c9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Cyclophosphamide
106 rdf:type schema:DefinedTerm
107 N0db21f88ebc444ad9b252be2d9df81fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Antibodies, Monoclonal, Murine-Derived
109 rdf:type schema:DefinedTerm
110 N1039191f2f6a4d0c9198d808a1dcf9fd rdf:first sg:person.0577376767.42
111 rdf:rest Ndc699bf2de484a6fa5825815aa259a52
112 N11cd9cc1ffd74c5f953a47639970af9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Aged, 80 and over
114 rdf:type schema:DefinedTerm
115 N13dc4b4d5c054141b8cb893c28f8c554 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Male
117 rdf:type schema:DefinedTerm
118 N1cc5c397f979451597d6b78808f83b06 rdf:first sg:person.01216742571.83
119 rdf:rest N1039191f2f6a4d0c9198d808a1dcf9fd
120 N1fa0260329a6497fbf1f34a593ab3eed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Retrospective Studies
122 rdf:type schema:DefinedTerm
123 N31b142c3fac44dc2a1c784793b906863 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Female
125 rdf:type schema:DefinedTerm
126 N4b5286045b024c698586c28d31b6d03c rdf:first sg:person.01325076175.04
127 rdf:rest N7a545897965545c98d9ad6c877701d55
128 N4ed71fb1e8884a6c9ea7f53c37eb2360 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Vincristine
130 rdf:type schema:DefinedTerm
131 N582b67e998054a1fb6250a61ddc08625 schema:volumeNumber 95
132 rdf:type schema:PublicationVolume
133 N604e4be5f5b34786b56e4dc0a0212efe rdf:first sg:person.01256762775.74
134 rdf:rest N4b5286045b024c698586c28d31b6d03c
135 N63e867d4cfe94d36b59dfbb8186bcdc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Doxorubicin
137 rdf:type schema:DefinedTerm
138 N65f5f94ab2b24d138bb22a8dfcd6a5e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Prednisone
140 rdf:type schema:DefinedTerm
141 N6c96d9c836af44ce98742fc75618b35d schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N6d0359c80c9643e6b2ae2bc78ffc5536 rdf:first sg:person.01007725661.75
144 rdf:rest Nf20974fbbc5e4a53b87347c340d91c68
145 N7a545897965545c98d9ad6c877701d55 rdf:first sg:person.0601472075.05
146 rdf:rest N87c60d5917e34c04aa4903e67b36cf40
147 N802e6cffd88140889f9c7204860f531d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Drug Administration Schedule
149 rdf:type schema:DefinedTerm
150 N87c60d5917e34c04aa4903e67b36cf40 rdf:first sg:person.01124154261.81
151 rdf:rest N1cc5c397f979451597d6b78808f83b06
152 N8c1354d9860e4ac29076a028f9ad5d87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Middle Aged
154 rdf:type schema:DefinedTerm
155 N9008329ef4af4f24a5b1482404b70f18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Antineoplastic Combined Chemotherapy Protocols
157 rdf:type schema:DefinedTerm
158 N909b52e9ecec4fc58402c9e1ae9be8f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Adult
160 rdf:type schema:DefinedTerm
161 N94db93691a024e5bb95c1fbb555bbe50 schema:name doi
162 schema:value 10.1007/s00277-015-2514-9
163 rdf:type schema:PropertyValue
164 N9dbb56e8fa924c6096243d834f397b36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Treatment Outcome
166 rdf:type schema:DefinedTerm
167 Na6f7ac0da1b64bcf88ae2fefaed68ba6 schema:name dimensions_id
168 schema:value pub.1013177223
169 rdf:type schema:PropertyValue
170 Nbe82df0311104ea3afffb921c7cc4b48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Aged
172 rdf:type schema:DefinedTerm
173 Nc0711977d0264f68b48890d5b0f7c761 schema:issueNumber 1
174 rdf:type schema:PublicationIssue
175 Nc402c8ae638a48a4955fa7bfdda897c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Humans
177 rdf:type schema:DefinedTerm
178 Nd069e81474e749fabdf09bac5ed5d557 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Lymphoma, Large B-Cell, Diffuse
180 rdf:type schema:DefinedTerm
181 Ndc699bf2de484a6fa5825815aa259a52 rdf:first sg:person.0656507753.24
182 rdf:rest rdf:nil
183 Ne87110c9192f4837b68615be96b0bb6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Rituximab
185 rdf:type schema:DefinedTerm
186 Nea157dd65df449a2bae90ff63f107f3a schema:name pubmed_id
187 schema:value 26435364
188 rdf:type schema:PropertyValue
189 Necec8cf130f04a8b88a2143933cd5253 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Survival Rate
191 rdf:type schema:DefinedTerm
192 Nf20974fbbc5e4a53b87347c340d91c68 rdf:first sg:person.0776770323.61
193 rdf:rest N604e4be5f5b34786b56e4dc0a0212efe
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
198 schema:name Oncology and Carcinogenesis
199 rdf:type schema:DefinedTerm
200 sg:journal.1358129 schema:issn 0939-5555
201 1432-0584
202 schema:name Annals of Hematology
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01007725661.75 schema:affiliation grid-institutes:grid.459661.9
206 schema:familyName Utsu
207 schema:givenName Yoshikazu
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007725661.75
209 rdf:type schema:Person
210 sg:person.01124154261.81 schema:affiliation grid-institutes:grid.459661.9
211 schema:familyName Masuda
212 schema:givenName Shinichi
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124154261.81
214 rdf:type schema:Person
215 sg:person.01216742571.83 schema:affiliation grid-institutes:grid.459661.9
216 schema:familyName Matsuura
217 schema:givenName Yasuhiro
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216742571.83
219 rdf:type schema:Person
220 sg:person.01256762775.74 schema:affiliation grid-institutes:grid.459661.9
221 schema:familyName Inagaki
222 schema:givenName Shunichirou
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256762775.74
224 rdf:type schema:Person
225 sg:person.01325076175.04 schema:affiliation grid-institutes:grid.459661.9
226 schema:familyName Arai
227 schema:givenName Hironori
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325076175.04
229 rdf:type schema:Person
230 sg:person.0577376767.42 schema:affiliation grid-institutes:grid.459661.9
231 schema:familyName Aotsuka
232 schema:givenName Nobuyuki
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577376767.42
234 rdf:type schema:Person
235 sg:person.0601472075.05 schema:affiliation grid-institutes:grid.459661.9
236 schema:familyName Yuasa
237 schema:givenName Hiromi
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601472075.05
239 rdf:type schema:Person
240 sg:person.0656507753.24 schema:affiliation grid-institutes:grid.459661.9
241 schema:familyName Wakita
242 schema:givenName Hisashi
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656507753.24
244 rdf:type schema:Person
245 sg:person.0776770323.61 schema:affiliation grid-institutes:grid.459661.9
246 schema:familyName Takaishi
247 schema:givenName Koji
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776770323.61
249 rdf:type schema:Person
250 sg:pub.10.1007/s00277-007-0399-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1037563009
251 https://doi.org/10.1007/s00277-007-0399-y
252 rdf:type schema:CreativeWork
253 sg:pub.10.1007/s00277-010-0956-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002676992
254 https://doi.org/10.1007/s00277-010-0956-7
255 rdf:type schema:CreativeWork
256 sg:pub.10.1038/bmt.2012.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028358194
257 https://doi.org/10.1038/bmt.2012.244
258 rdf:type schema:CreativeWork
259 sg:pub.10.1186/1756-9966-28-116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027098559
260 https://doi.org/10.1186/1756-9966-28-116
261 rdf:type schema:CreativeWork
262 sg:pub.10.1186/s12885-015-1287-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021003853
263 https://doi.org/10.1186/s12885-015-1287-9
264 rdf:type schema:CreativeWork
265 grid-institutes:grid.459661.9 schema:alternateName Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan
266 schema:name Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 90-1 Iida-cho, 286-8523, Narita, Japan
267 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...